Defense against filoviruses used as biological weapons (Q33964682)

30 July 2017

1 reference

title

Defense against filoviruses used as biological weapons (English)

1 reference

30 July 2017

1 reference

1

Mike Bray

1 reference

30 July 2017

1 January 2003

1 reference

30 July 2017

1 reference

30 July 2017

57

1 reference

30 July 2017

1-2

1 reference

30 July 2017

53-60

1 reference

The Ebola virus VP35 protein functions as a type I IFN antagonist.

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Hemorrhagic fever viruses as biological weapons: medical and public health management

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

The role of the Type I interferon response in the resistance of mice to filovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Experimental therapy of filovirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Biological warfare. A historical perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

A case of Ebola virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Rapid identification of Ebola virus and related filoviruses in fluid specimens using indirect immunoelectron microscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Evaluation in nonhuman primates of vaccines against Ebola virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

An outbreak of Ebola virus: lessons for everyday activities in the intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Marburg virus vaccines: comparing classical and new approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Marburg agent disease: In man

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Ebola virus can be effectively neutralized by antibody produced in natural human infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Unexpected Ebola virus in a tertiary setting: clinical and epidemiologic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Public health assessment of potential biological terrorism agents

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Infection and activation of monocytes by Marburg and Ebola viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Development of a preventive vaccine for Ebola virus infection in primates

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Immunization for Ebola virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Ebola virus: the search for vaccines and treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

Epitopes involved in antibody-mediated protection from Ebola virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidémies à Kikwit

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900200-0

7 January 2021

10.1016/S0166-3542(02)00200-0

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

12615303